ABCSG 18: monoclonal antibody increases disease-free survival in breast cancer
Giving a monoclonal antibody (denosumab) as adjuvant therapy with aromatase inhibitors in postmenopausal, hormone-receptor-positive breast cancer patients reduces the relapse rate by 18%.